RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0–2 M0 non-small cell lung cancer

Background The clinical outcomes of patients with resected T 1-3 N 0–2 M 0 non-small cell lung cancer (NSCLC) with the same tumor-node-metastasis (TNM) stage are diverse. Although other prognostic factors and prognostic prediction tools have been reported in many published studies, a convenient, acc...

Full description

Saved in:
Bibliographic Details
Published inBioData mining Vol. 12; no. 1; pp. 17 - 14
Main Authors Zhang, Yunkui, Li, YaoChen, Zhang, Rongsheng, Zhang, Yujie, Ma, Haitao
Format Journal Article
LanguageEnglish
Published London BioMed Central 23.08.2019
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects
Online AccessGet full text
ISSN1756-0381
1756-0381
DOI10.1186/s13040-019-0205-0

Cover

More Information
Summary:Background The clinical outcomes of patients with resected T 1-3 N 0–2 M 0 non-small cell lung cancer (NSCLC) with the same tumor-node-metastasis (TNM) stage are diverse. Although other prognostic factors and prognostic prediction tools have been reported in many published studies, a convenient, accurate and specific prognostic prediction software for clinicians has not been developed. The purpose of our research was to develop this type of software that can analyze subdivided T and N staging and additional factors to predict prognostic risk and the corresponding mean and median survival time and 1–5-year survival rates of patients with resected T 1-3 N 0–2 M 0 NSCLC. Results Using a Cox proportional hazard regression model, we determined the independent prognostic factors and obtained a prognostic index (PI) eq. PI = ∑ βixi . =0.379X 1 –0.403X 2 –0.267X 51 –0.167X 61 –0.298X 62  + 0.460X 71  + 0.617X 72 –0.344X 81 –0.105X 91 –0.243X 92  + 0.305X 101  + 0.508X 102  + 0.754X 103  + 0.143X 111  + 0.170X 112  + 0.434X 113 –0.327X 122 –0.247X 123  + 0.517X 133  + 0.340X 134  + 0.457X 143  + 0.419X 144  + 0.407X 145 . Using the PI equation, we determined the PI value of every patient. According to the quantile of the PI value, patients were divided into three risk groups: low-, intermediate-, and high-risk groups with significantly different survival rates. Meanwhile, we obtained the mean and median survival times and 1–5-year survival rates of the three groups. We developed the RNSCLC-PRSP software which is freely available on the web at http://www.rnsclcpps.com with all major browsers supported to determine the prognostic risk and associated survival of patients with resected T 1-3 N 0–2  M 0 non-small cell lung cancer. Conclusions After prognostic factor analysis, prognostic risk grouping and corresponding survival assessment, we developed a novel software program. It is practical and convenient for clinicians to evaluate the prognostic risk and corresponding survival of patients with resected T 1-3 N 0–2 M 0 NSCLC. Additionally, it has guiding significance for clinicians to make decisions about complementary treatment for patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1756-0381
1756-0381
DOI:10.1186/s13040-019-0205-0